Section/item	ltem No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page1/Line1-3	Title/Paragraph1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page1/Line16-Page2/Line53	Abstract/ Paragraph1-4
Introduction		·		
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page2/Line55-Page3/Line79	Introduction/ Paragraph1-
Objectives	3	State specific objectives, including any prespecified hypotheses	Page3/Line80-81	Introduction/ Paragraph4
Methods			·	
Study design	4	Present key elements of study design early in the paper	Page3/Line86	Methods/Paragraph1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page3/Line86-89	Methods/Paragraph1
Participants	6	<ul> <li>(a) <i>Cohort study</i>—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</li> <li><i>Case-control study</i>—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</li> <li><i>Cross-sectional study</i>—Give the eligibility criteria, and the sources and methods of selection of participants</li> </ul>	Page3/Line89-94	Methods/Paragraph1
		(b) <b>Cohort study</b> —For matched studies, give matching criteria and number of exposed and unexposed <b>Case-control study</b> —For matched studies, give matching criteria and the number of controls per case	Don't match study	Don't match study
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page5/Line136-Page6/Line181	Methods/Paragraph4-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page4/Line113-Page5/Line135	Methods/Paragraph3
Bias	9	Describe any efforts to address potential sources of bias	Page3/Line86-89	Methods/Paragraph1
Study size	10	Explain how the study size was arrived at	Page3/Line86-89	Methods/Paragraph1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page4/Line136-Page6/Line179	Methods/Paragraph4-8

## STROBE Statement-checklist of items that should be included in reports of observational studies

		1	Γ
12	(a) Describe all statistical methods, including those used to control for confounding	Page6/Line184-186	Statistical analysis/Paragrap
	(b) Describe any methods used to examine subgroups and interactions	Page6/Line186-190	Statistical analysis/Paragra
	(c) Explain how missing data were addressed	Page6/Line190-191	Statistical analysis/Paragrap
	(d) <b>Cohort study</b> —If applicable, explain how loss to follow-up was addressed <b>Case-control study</b> —If applicable, explain how matching of cases and controls was addressed <b>Cross-sectional study</b> —If applicable, describe analytical methods taking account of sampling strategy	Page6/Line191-195	Statistical analysis/Paragrap
	(e) Describe any sensitivity analyses	Page6/Line191-195	Statistical analysis/Paragrap
13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page6/Line198-Page7/Line205	Results/Paragraph1
	(b) Give reasons for non-participation at each stage	Page6/Line198-199	Results/Paragraph1
	(c) Consider use of a flow diagram	Page15/Line487-505	Fig.1
14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page7/Line206-215	Results/Paragraph2
	(b) Indicate number of participants with missing data for each variable of interest	Page7/Line204-205	Results/Paragraph1
	(c) <b>Cohort study</b> —Summarise follow-up time (eg, average and total amount)	Don't match study +	Don't match study +
15*	Cohort study-Report numbers of outcome events or summary measures over time	Don't match study +	Don't match study +
	Case-control study – Report numbers in each exposure category, or summary measures of exposure	Don't match study +	Don't match study +
	Cross-sectional study – Report numbers of outcome events or summary measures	Page6/Line198-Page7/Line203	Results/Paragraph1
16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page7/Line232-Page8/Line245	Results/Paragraph4
	(b) Report category boundaries when continuous variables were categorized	Page7/Line206-215	Results/Paragraph2
	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page7/Line216-229	Results/Paragraph3
17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses	No other analyses were performed	No other analyses were performed
18	Summarise key results with reference to study objectives	Page8/Line251-257	Discussion/Paragraph2
19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page10/Line326-330	Discussion/Paragraph9
	13* 14* 15* 16 17 18	13*       (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed       (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed         (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed         (b) Give reasons for non-participation at each stage       (c) Consider use of a flow diagram         14*       (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders         (b) Indicate number of participants with missing data for each variable of interest       (c) Cohort study—Report numbers of outcome events or summary measures over time         Case-control study—Report numbers of outcome events or summary measures       (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included         (b) Report category boundaries when continuous variables were categorized       (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period         16       Summarise key results with reference to study objectives       19         18       Summarise key results with reference to study objectives </td <td>12       (a) Describe any methods, including index data of control for control index controls and interactions       Page/fLine186-190         (b) Describe any methods used to examine subgroups and interactions       Page/fLine186-190         (c) Explain how missing data were addressed       Page/fLine186-190         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed       Page/fLine191-195         (e) Describe any sensitivity analyses       Page/fLine191-195         13<sup>*</sup>       (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed       Page/fLine198-Page/fLine205         14<sup>*</sup>       (a) Report numbers of individuals at each stage       Page/fLine198-Page/fLine205       Page/fLine198-Page/fLine205         14<sup>*</sup>       (a) Give reasons for non-participation at each stage       Page/fLine198-Page/fLine205-215       Page/fLine206-215         14<sup>*</sup>       (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders       Page/fLine204-205       Page/fLine204-205         15<sup>*</sup>       Cohort study—Report numbers of outcome events or summary measures of exposure       Don't match study       Page/fLine204-205         16       (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interva). Make clear which confounders were adjusted for</td>	12       (a) Describe any methods, including index data of control for control index controls and interactions       Page/fLine186-190         (b) Describe any methods used to examine subgroups and interactions       Page/fLine186-190         (c) Explain how missing data were addressed       Page/fLine186-190         (d) Cohort study—If applicable, explain how matching of cases and controls was addressed       Page/fLine191-195         (e) Describe any sensitivity analyses       Page/fLine191-195         13 <sup>*</sup> (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed       Page/fLine198-Page/fLine205         14 <sup>*</sup> (a) Report numbers of individuals at each stage       Page/fLine198-Page/fLine205       Page/fLine198-Page/fLine205         14 <sup>*</sup> (a) Give reasons for non-participation at each stage       Page/fLine198-Page/fLine205-215       Page/fLine206-215         14 <sup>*</sup> (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders       Page/fLine204-205       Page/fLine204-205         15 <sup>*</sup> Cohort study—Report numbers of outcome events or summary measures of exposure       Don't match study       Page/fLine204-205         16       (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interva). Make clear which confounders were adjusted for

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page8/Line258-Page10/Line325	Discussion/Paragraph3-8			
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page10/Line323-325	Discussion/Paragraph8			
Other information							
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page11/Line338	Footnotes			

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/apm-21-2722

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.